“Global Biotech Company Focusing on SynThese^TM platform-based Antibody Drug Development”

HuMab’s vision is growing into a global biopharma company that focuses on developing innovative therapeutic interventions for patients with medical unmet needs by utilizing SynThese^TM transgenic mouse platform, developed from our proprietary AiCE®(Artificial interspecies Chromosome Exchange) technology, and by establishing strategic alliances with global pharmaceuticals.